title: [Resistance to curative treatment by unfractionned heparin].
abstract: Unfractionated heparin has been used as antithrombotic therapy for many years. Its main effect is attributed to the activation of antithrombin (AT), the heparin/AT complex inactivating both factor IIa (thrombin) and factor Xa. Resistance to unfractionated heparin with clinical or biological expression is uncommon. The occurrence of venous or arterial thrombosis or the extension of thrombosis in a patient receiving unfractionated heparin, should always raise suspicion of either AT deficiency or type 2 heparin-induced thrombocytopenia (HIT type 2). HIT type 2 is not a true heparin resistance but an immune complication that requires heparin discontinuation and the use of alternative anticoagulants. Biological heparin resistance is suspected in the presence of a normal or not prolonged activated partial thromboplastin time despite the administration of increasing dose of heparin. Measurement of anti-Xa activity is useful to adjust heparin treatment. Isolated biological heparin resistance is encountered in several physiological and pathological situations including inflammatory and infectious disorders, pregnancy and thrombocytosis. It also occurs in acquired antithrombin deficiency of nephrotic syndrome, l-asparaginase treatment or cardiopulmonary bypass. Biological heparin resistance is relatively common, but clinically significant resistance to heparin is rare and should always raise suspicion of either AT deficiency or type 2 heparin-induced thrombocytopenia.
authors.affiliation: Laboratoire d'hématologie, hôpital Charles-Nicolle, boulevard 9-Avril, Tunis 1006, Tunisie.
authors.forename: S
authors.initials: S
authors.lastname: Guermazi
authors.forename: R
authors.initials: R
authors.lastname: Znazen
mesh_terms: D000991:Antithrombins / Q000172:deficiency*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D004351:Drug Resistance; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D013921:Thrombocytopenia / Q000139:chemically induced*; D013927:Thrombosis / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000188:drug therapy*
chemical_list: D000991:Antithrombins; D005343:Fibrinolytic Agents; D006493:Heparin